🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Finding relevant papers for literature review takes a lot of time. So, MIT researchers built Undermind, an AI-powered search engine. It can generate well-researched overviews on any topic and is 10-50 times better than Google Scholar. Here's how to use it:

Thank you Dr. Avila-Flores the entire The Avila-Flores laboratory and Auburn University for inviting me to talk about our ILLUMINATE trial and our research on head and neck cancer metabolism. Also a special thanks to VCOM-Auburn!

baransumer Thank you, Dr. Sumer, for your visit and for your contributions to advancing nanomedicine into the clinical practice. Our students and faculty COSAM and VCOM - Auburn Campus enjoyed your seminar. I highly recommend reading doi.org/10.1038/s41551…

Congratulations to Shuqing and my fellow coauthors on our study demonstrating a correlation between nodal yield from neck dissection and the presence of tertiary lymphoid structures in the primary tumors of patients with head and neck cancer. onlinelibrary.wiley.com/doi/10.1002/he…

Protocol Activation! NRG-HN014 "Randomized Phase III Trial of Neoadjuvant Immunotherapy With Response-Adapted Treatment Versus Standard-of-Care Treatment for Resectable Stage III/IV Cutaneous Squamous Cell Carcinoma” is open to patient entry. conta.cc/4ftFlhD Neil D. Gross, MD, FACS

Honored to be part of interdisciplinary team to promote UT Southwestern Medical Center. Magic place to ignite collaboration with Dr. Baran Sumer baransumer to advance cancer surgery and immunotherapy!

Thank you, Stephan and organisers!

Thank you to #UTSW Professor Daniel Siegwart, Ph.D., who delivered an outstanding first presentation for this year’s President’s Lecture Series! It was a brilliant discussion of “Innovation in Nanotechnology: From Vaccines to Novel Genetic Disease Treatment.”

We are thrilled to announce that EA3211 now includes *metachronous* oligometastatic disease, provided the primary site has been disease-free for at least 6 months. Please consider opening up this study to answer this important question in metastatic HNSCC!

AHNS Pre-Meeting Course at COSM 2025 AHNS Innovation and Entrepreneurship Symposium (Non-CME) May 13, 2025 at the Hyatt Regency New Orleans Introductory, all-day course designed for surgeons and academic physicians Register today! ahns.info/meetings/ahns-… #AHNS #AHNS2025 #COSM2025

Artificial Intelligence in Management of H&N Cancer: New Horizons Presented by the AHNS Population Health & Clinical Research Service#AHNS #AHNS2025 #COSM2025 #AI

Join Us! Wednesday, May 14th at 3:15-4:00 PM in Celestin E "More than Skin Deep: Reviewing 'Respectability' for Cutaneous Malignancies" Moderated by Karen Choi, MD #AHNS #AHNS2025 #COSM2025

Join us in 30 minutes at 7:00 AM for the AHNS New Member Induction Ceremony and Research Award Ceremony. Celebrate the new members and Award winners! 7:00 am-8:00 am in Celstin D #AHNS #AHNS2025 #COSM2025

Come hear the AHNS Presidential Introduction at 8:00 AM with Dr. Lydiatt's Presidential Address to follow at 8:15 AM. Join us in Room Celestin D! #AHNS #AHNS2025 #COSM2025

Grateful for another successful AHNS Innovation and Entrepreneurship Symposium alongside my co-director, Jose Zevallos! Thank you to AHNS for the opportunity to bring this program back, and to all the incredible faculty and attendees who made it possible! #AHNS #AHNS2025

Congratulations to Zhijian "James" Chen, Ph.D., Professor of Molecular Biology UT Southwestern Medical Center, on being elected to the U.K.'s The Royal Society, the world's oldest scientific academy.

Check out Medical Vision Goggles, which help surgeons eliminate all cancer cells after tumor removal. Inventor Samuel Achilefu, Ph.D., Chair of UT Southwestern Biomedical Engineering, discusses the goggles and his goal of making them available to surgeons worldwide. bit.ly/3F6qAFg #UTSWScience

#BREAKING The FDA has approved pembrolizumab as the first new standard-of-care treatment for patients with resectable locally advanced #HeadandNeck cancer in 20+ years. Approval based on the pivotal KEYNOTE-689 trial led by Ravi Uppaluri, MDPhD of the Dana-Farber Brigham Cancer Center.

Exciting news in the head and neck cancer space. KEYNOTE-689 resulted in the first FDA approval for patients with HNSCC in 6 years. Congrats to Ravi Uppaluri, MDPhD, Doug Adkins, and the rest of the team worldwide. fda.gov/drugs/resource…